New Guidelines Call For Earlier Diagnosis, Intervention in Feline Dental Disease

Dechra announced FDA approval of Emeprev, a maropitant citrate injectable solution for the prevention and treatment of vomiting in dogs and cats. With this approval, Dechra becomes the first to offer an FDA-approved bioequivalent injectable alternative to the most widely used Veterinary antiemetic. Emeprev is approved for acute vomiting in dogs and for vomiting in cats, providing veterinarians with a convenient in-clinic option.

Clinical data supporting approval included a blinded crossover study in healthy beagle dogs showing that the benzyl alcohol–preserved formulation used in Emeprev caused significantly less injection pain than metacresol-preserved maropitant products, such as Cerenia from Zoetis, at both refrigerated and room temperatures. Because Emeprev does not require refrigeration, it may also streamline clinic workflows. Dechra leaders highlighted the product’s role in meeting real-world clinical needs and strengthening the human–animal bond. Emeprev will be available through major Veterinary distributors in early 2026, with specific age and use limitations noted on the label.